SEASICKNESS - CURRENT STATE OF PREVENTION AND TREATMENT ISSUE

Cover Page

Cite item

Full Text

Abstract

The paper describes the current state of development of seasickness as one of movement disease variants. The given type of pathology occurs when combining different types of ship’s motion (rolling and pitching). Circular, vertical and slow movements induce more pronounced and frequent signs of seasickness than linear, horizontal and quick ones. In the view of majority of researchers, the most likely is an intersensory conflict theory i.e. violation of coherent functioning of afferent body systems performing spatial orientation, statokinetic equilibrium and keeping balance. The leading role is played by the functional dysfunction of the vestibular analyzer. The classification of means of preventing and stopping of motion sickness is given, the mechanisms of their action, specific activity and side effects are described. It has been shown that currently the most effective drugs are M-cholinergic antagonists (scopolamine hydrobromide) and H1-histamine antagonists of the 1st generation (dimenhydrinate, diphenhydramine, cyclizine, meclizine, promethazine, etc.). Of the antipsychotics and blockers of D2 receptors, prochlorperazine and metoclopramide are recommended. It is also worth to use prokinetics (domperidone, cisapride, renzapride, etc.), tranquilizers (barbiturates, benzodiazepines), sleeping pills and local anesthetics. Particular attention is paid to combination drugs, consisting of antiemetic and psychostimulating drugs, designed to maintain working capacity under the influence of seasickness factors on the body. Non-pharmacological means of preventing seasickness and alleviating its symptoms are described. The main directions of improving the system of measures aimed at maintaining efficiency in the presence of symptoms of seasickness are determined. 

About the authors

I. S. Drachev

Research and Test Institute of Military Medicine of the Ministry of Defense of the Russian Federation

Author for correspondence.
Email: dr.ingwar@mail.ru
Saint Petersburg Russian Federation

V. I. Legeza

S. M. Kirov Military Medical Academy

Email: fake@neicon.ru
Saint Petersburg Russian Federation

A. B. Seleznev

Research and Test Institute of Military Medicine of the Ministry of Defense of the Russian Federation

Email: alexseleznov@list.ru
Saint Petersburg Russian Federation

References

  1. Zhang L.L., Wang J.Q., Qi R.R. et al. Motion Sickness: Current Knowledge and Recent Advance // CNS Neurosci. Ther. 2016. Vol. 22, No. 1. P. 15–24.
  2. Shupak A., Gordon C.R. Motion sickness: advances in pathogenesis, prediction, prevention, and treatment // Aviat. Space Environ. Med. 2006. Vol. 77, No. 12. P. 1213–1223.
  3. Koch A., Cascorbi I., Westhofen M. et al. The Neurophysiology and Treatment of Motion Sickness // Dtsch. Arztebl. Int. 2018. Vol. 115 (41). P. 687–696.
  4. Sanger G.J., Andrews P.L.R. A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research // Front Pharmacol. 2018. Vol. 9, art. 913. P. 1–35.
  5. Барнацкий В.И. Морская болезнь. М.: Медицина, 1983. 144 с.
  6. Brainard A., Gresham C. Prevention and treatment of motion sickness // Am. Fam. Physician. 2014. Vol. 90, No. 1. P. 41–46.
  7. Koch K.L. Hasler W.L. Nausea and Vomiting. Diagnosis and Treatment. Springer International Publishing Switzerland, 2017, 224 p.
  8. Lackner J.R. Motion sickness: more than nausea and vomiting // Exp. Brain Res. 2014. Vol. 232, No. 8. P. 2493–2510.
  9. Riola J.M, Pérez R. The seasickness phenomenom // J. Marit. Res. 2012. Vol. 9, No. 2. P. 67–72.
  10. Huppert D., Oldelehr H., Krammling B. et al. What the ancient Greeks and Romans knew (and did not know) about seasickness // Neurology. 2016. Vol. 86, No. 6. P. 560–565.
  11. Huppert D., Benson J., Brandt T. A Historical View of Motion Sickness-A Plague at Sea and on Land, Also with Military Impact // Front. Neurol. 2017. Vol. 8, Art. 114. P. 1–15.
  12. Brandt T., Bauer M., Benson J., Huppert D. Motion sickness in ancient China: Seasickness and cart-sickness // Neurology. 2016. Vol. 87, No. 3. P. 331–335.
  13. Irwin J.A., Cantab M.A., Dub M.D. The Pathology of sea-sickness // Lancet. 1881. Vol. 118, Iss. 3039. P. 907–909.
  14. Reason J.T. Motion sickness — some theoretical considerations // Int. J. of Man-Machine Studies. 1969. Vol. 1, Iss. 1. P. 21–38.
  15. Riccio G.E., Stoffregen T.A. An ecological theory of motion sickness and postural instability // Ecol. Psychol. 1991. Vol. 3, No. 3. P. 195–240.
  16. Oman C.M. Are evolutionary hypotheses for motion sickness «just-so» stories? // J. Vestib. Res. 2012. Vol. 22, No. 2. P. 117–127.
  17. Golding J.F., Gresty M.A. Pathophysiology and treatment of motion sickness // Curr. Opin. Neurol. 2015. Vol. 28. P. 83–88.
  18. Bertolini G., Straumann D. Moving in a moving world: a review on vestibular motion sickness // Front Neurol. 2016. Vol. 7, Art. 14. P. 1–11.
  19. Oman C.M., Cullen K.E. Brainstem processing of vestibular sensory exafference: implications for motion sickness etiology // Exp. Brain. Res. 2014. Vol. 232, No. 8. P. 2483–2492.
  20. Holstein G.R., Friedrich V.L. Jr., Kang T. et al. Direct projections from the caudal vestibular nuclei to the ventrolateral medulla in the rat // Neuroscience. 2011. Vol. 175. P. 104–117.
  21. Yates B.J., Bolton P.S., Macefield V.G. Vestibulo-sympathetic responses // Compr. Physiol. 2014. Vol. 4, No. 2. P. 851–887.
  22. Yates B.J., Catanzaro M.F., Miller D.J., McCall A.A. Integration of vestibular and emetic gastrointestinal signals that produce nausea and vomiting: potential contributions to motion sickness // Exp. Brain. Res. 2014. Vol. 232, No. 8. P. 2455–2469.
  23. Otto B., Riepl R.L., Klosterhalfen S., Enck P. Endocrine correlates of acute nausea and vomiting // Auton. Neurosci. 2006. Vol. 129, No. 1–2. P. 17–21.
  24. Camilleri M., Papathanasopoulos A., Odunsi S.T. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders // Nat. Rev. Gastroenterol. Hepatol. 2009. Vol. 6, No. 6. P. 343–352.
  25. Schmäl F. Neuronal mechanisms and the treatment of motion sickness // Pharmacology. 2013. Vol. 91, No. 3–4. P. 229–241.
  26. Foubert J., Vaessen G. Nausea: the neglected symptom? // Eur. J. Oncol. Nurs. 2005. Vol. 9, No 1. P. 21–32.
  27. Stern R.M., Koch K.L., Nausea A.P. Mechanisms and Management. Oxford University Press, 2011. 480 p.
  28. Nalivaiko E., Rudd J.A., So R.H. Motion sickness, nausea and thermoregulation: The «toxic» hypothesis // Temperature (Austin). 2014. Vol. 1, No. 3. P. 164–171.
  29. Napadow V., Sheehan J.D., Kim J. et al. The brain circuitry underlying the temporal evolution of nausea in humans // Cereb. Cortex. 2013. Vol. 23, No 4. P. 806–813.
  30. Golding J.F. Motion sickness susceptibility // Auton. Neurosci. 2006. Vol. 129, No. 1–2. P. 67–76.
  31. Paillard A.C., Quarck G., Paolino F.et al. Motion sickness susceptibility in healthy subjects and vestibular patients: effects of gender, age and trait-anxiety // J. Vestib. Res. 2013. Vol. 23, No. 4–5. P. 203–209.
  32. Sharon J.D., Hullar T.E. Motion sensitivity and caloric responsiveness in vestibular migraine and Meniere’s disease // Laryngoscope. 2014. Vol. 124, No. 4. P. 969–973.
  33. Hasler W.L. Newest Drugs for Chronic Unexplained Nausea and Vomiting // Curr. Treat Options Gastroenterol. 2016. Vol. 14, No. 4. P. 371–385.
  34. Машковский М.Д. Лекарственные средства. 16-е изд. М.: Новая волна, 2016. 1216 с.
  35. Фармакология: учебник / под ред. Р.Н. Аляутдина. 5-е изд. М.: ГЭОТАР-мед, 2018. 1104 с.
  36. Sherman C.R. Motion sickness: review of causes and preventive strategies // J. Travel Med. 2002. Vol. 9, No. 5. P. 251–256.
  37. Spinks A., Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness // Cochrane Database Syst. Rev. 2011. No. 6. CD002851. doi: 10.1002/14651858.CD002851.pub4.
  38. Gil A., Nachum Z., Tal D., Shupak A. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study // Clin. Neuropharmacol. 2012. Vol. 35, No. 1. P. 37–39.
  39. Church M.K., Church D.S. Pharmacology of antihistamines // Indian J. Dermatol. 2013. Vol. 58, No. 3. P. 219–224.
  40. Nachum Z., Shupak A., Gordon C.R. Transdermal scopolamine for prevention of motion sickness: clinical pharmacokinetics and therapeutic applications // Clin. Pharmacokinet. 2006. Vol. 45, No. 6. P. 543–566.
  41. McDonald K., Trick L., Boyle J. Sedation and antihistamines: an update. Review of inter‐drug differences using proportional impairment ratios // Hum. Psychopharmacol. 2008. Vol. 23, No. 7. P. 555–570.
  42. Murdin L., Golding J., Bronstein A. Managing motion sickness // B.M.J. 2011. Vol. 343. d7430. 7 p.
  43. Leggio G.M., Bucolo C., Platania C.B. et al. Current drug treatments targeting dopamine D3 receptor // Pharmacol. Ther. 2016. Vol. 165. P. 164–177.
  44. Hershkovitz D., Asna N., Shupak A., Kaminski G., Bar R., Tal D. Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea // Aviat. Space Environ. Med. 2009. Vol. 80, No. 7. P. 643–646.
  45. Rock E.M., Parker L.A. Cannabinoids as potential treatment for chemotherapy-induced nausea and vomiting // Front Pharmacol. 2016. Vol. 7, Art. 221. P. 1–10.
  46. Muth E.R., Elkins A.N. High dose ondansetron for reducing motion sickness in highly susceptible subjects // Aviat. Space Environ. Med. 2007. Vol. 78, No. 7. P. 686–692.
  47. Chiu L., Chow R., Popovic M. et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis // Support Care Cancer. 2016. Vol. 24, No. 5. P. 2381–2392.
  48. Chu C.C., Hsing C.H., Shieh J.P. et al. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting // Eur. J. Pharmacol. 2014. Vol. 722. P. 48–54.
  49. Guttuso T.Jr. Gabapentin’s anti-nausea and anti-emetic effects: a review // Exp. Brain Res. 2014. Vol. 232, No. 8. P. 2535–2539.
  50. Hoffman T. Ginger: an ancient remedy and modern miracle drug // Hawaii Med. J. 2007. Vol. 66, No. 12. P. 326–327.
  51. Weinstein S.E., Stern R.M. Comparison of marezine and dramamine in preventing symptoms of motion sickness // Aviat. Space Environ. Med. 1997. Vol. 68, No. 10. P. 890–894.
  52. Bos J.E., MacKinnon S.N., Patterson A. Motion sickness symptoms in a ship motion simulator: effects of inside, outside, and no view // Aviat. Space Environ. Med. 2005. Vol. 76, No. 12. P. 1111–1118.
  53. Yen Pik Sang F.D., Billar J.P., Golding J.F., Gresty M.A. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape // J. Travel Med. 2003. Vol. 10, No. 2. P. 108–111.
  54. Wada T., Konno H., Fujisawa S., Doi S. Can passengers’ active head tilt decrease the severity of carsickness? Effect of head tilt on severity of motion sickness in a lateral acceleration environment // Hum. Factors. 2012. Vol. 54, No. 2. P. 226–234.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies